Fig. 2

Forest plots of AR-V7-positive proportion in newly diagnosed PCa and CRPC from fifteen studies. AR-V7-positive proportion in newly diagnosed PCa and CRPC were calculated using random-effect models. Subgroup analyses were performed based on various AR-V7 detection assays. The bars indicate 95% CIs. AR-V7 androgen receptor splicing variant 7, CRPC castration-resistant prostate cancer, PCa prostate cancer, CI confidence interval, OR odds ratio, CTC circulating tumor cell, RISH RNA in situ hybridization, IHC immunohistochemistry, ctRNA circulating tumor RNA